当前位置: X-MOL 学术World J. Stem Cells › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Different kinds of stem cells in the development of SARS-CoV-2 treatments.
World Journal of Stem Cells ( IF 3.6 ) Pub Date : 2021-6-18 , DOI: 10.4252/wjsc.v13.i5.439
Monica Maribel Mata-Miranda 1 , Miguel Sanchez-Brito 2 , Gustavo Jesus Vazquez-Zapien 3
Affiliation  

On February 11, 2020, the World Health Organization officially announced the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as an emerging recent pandemic illness, which currently has approximately taken the life of two million persons in more than 200 countries. Medical, clinical, and scientific efforts have focused on searching for new prevention and treatment strategies. Regenerative medicine and tissue engineering focused on using stem cells (SCs) have become a promising tool, and the regenerative and immunoregulatory capabilities of mesenchymal SCs (MSCs) and their exosomes have been demonstrated. Moreover, it has been essential to establishing models to reproduce the viral life cycle and mimic the pathology of COVID-19 to understand the virus's behavior. The fields of pluripotent SCs (PSCs), induced PSCs (iPSCs), and artificial iPSCs have been used for this purpose in the development of infection models or organoids. Nevertheless, some inconveniences have been declared in SC use; for example, it has been reported that SARS-CoV-2 enters human cells through the angiotensin-converting enzyme 2 receptor, which is highly expressed in MSCs, so it is important to continue investigating the employment of SCs in COVID-19, taking into consideration their advantages and disadvantages. In this review, we expose the use of different kinds of SCs and their derivatives for studying the SARS-CoV-2 behavior and develop treatments to counter COVID-19.

中文翻译:


SARS-CoV-2 治疗开发中的不同种类干细胞。



2020 年 2 月 11 日,世界卫生组织正式宣布由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的 2019 年冠状病毒病(COVID-19)为近期新出现的大流行性疾病,目前大约已200 多个国家 200 万人的生活。医学、临床和科学工作的重点是寻找新的预防和治疗策略。专注于使用干细胞(SC)的再生医学和组织工程已成为一种有前途的工具,并且间充质SC(MSC)及其外泌体的再生和免疫调节能力已得到证明。此外,建立模型来重现病毒生命周期并模拟 COVID-19 的病理学以了解病毒的行为至关重要。多能 SC (PSC)、诱导 PSC (iPSC) 和人工 iPSC 领域已用于开发感染模型或类器官。尽管如此,SC 使用仍存在一些不便;例如,据报道,SARS-CoV-2通过血管紧张素转换酶2受体进入人体细胞,该受体在MSCs中高度表达,因此继续研究SCs在COVID-19中的应用非常重要,考虑到考虑它们的优点和缺点。在这篇综述中,我们揭示了使用不同种类的 SC 及其衍生物来研究 SARS-CoV-2 行为并开发对抗 COVID-19 的治疗方法。
更新日期:2021-06-23
down
wechat
bug